Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process

A technology for tripterygium glycosides and glomerulosclerosis, applied in the field of delaying the process of focal segmental glomerulosclerosis, Phellinus linteus and tripterygium wilfordii polyglycosides, can solve problems such as undiscovered, reduce toxicity, improve cardiac The effect of damage and alleviation of renal damage

Active Publication Date: 2020-08-11
HANGHZOU HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the research on Phellinus Phellinus covers many of the fields mentioned above, and new researches continue to emerge, so far, there are few reports on the research and application of Phellinus Phellinus in the protection of chronic kidney disease at home and abroad. No related records found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process
  • Combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process
  • Combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Effect of Phellinus and Tripterygium Glycosides on Urinary Protein in FSGS Rats

[0030] Experimental results such as figure 1 As shown, the 24 h urine protein (24 h Pro) in the model group was significantly higher than that in the control group, the 24 h urinary protein in the Phellinus group and each intervention group was lower than that of the model group in the fourth week, and the Phellinus group in the tenth week Compared with the model group, the combined tripterygium glycosides group significantly reduced urinary protein, and Phellinus or Tripterygium glycosides alone could also significantly reduce urinary protein, but there was no statistical significance compared with the model group.

Embodiment 2

[0031] Example 2 Effect of Phellinus and Tripterygium Glycosides on Renal Function of FSGS Rats

[0032] Experimental results such as figure 2 As shown, the serum creatinine (Serum creatinine, Scr) and urea nitrogen (Bloodurea nitrogen, BUN) of the rats in the model group were significantly higher than those of the control group, and the Scr values ​​of each intervention group were significantly lower than those of the model group. BUN was significantly lower than the model group, and significantly lower than the Phellinus or Tripterygium glycosides alone intervention group, and there was no statistically significant difference between the BUN level of the single medication group and the model group.

Embodiment 3

[0033] Example 3 Effects of Phellinus and Tripterygium Polyglycosides on Blood Lipids of FSGS Rats

[0034] The experimental results are shown in Table 1. Serum triglyceride (Tglyceride, TG), cholesterol (Total Cholesterol, TC) and low density lipoprotein (Low density lipoprotein, LDL) in the FSGS nephropathy rat model group were significantly higher than those in the control group. TG and TC in the treatment group were significantly lower than those in the model group, LDL levels in the Phellinus and Tripterygium glycosides group were significantly lower than those in the model group, and TG and LDL levels were significantly lower than those in the Phellinus or Tripterygium glycosides alone intervention group, but there was no statistical difference. significance.

[0035] Table 1

[0036]

[0037] Note: Compared with the normal group, a p b p <0.05.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of phellinus igniarius and tripterygium glycosides in delaying a focal segmental glomerulosclerosis process. The combined phellinus igniarius and tripterygium glycosides can significantly reduce urine protein, reduce serum creatinine and urea nitrogen of rats, reduce serum triglyceride, cholesterol and low-density lipoprotein, and reduce the amount of creatine kinase, creatine kinase isozyme and glutamic-pyruvic transaminase. The phellinus igniarius water decoction is combined with the tripterygium glycosides for use, so that the toxicity of the tripterygium glycosides can be reduced and the heart injury can be improved on the basis of ensuring the original effects of the tripterygium glycosides on relieving the renal function injury of FSGS rats, reducing blood fat and the like, and the application prospect is wide.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicines, in particular to the use of Phellinus radix and tripterygium glycosides in delaying the progress of focal segmental glomerulosclerosis. Background technique [0002] Chronic kidney disease (chronic kidney disease, CKD) has become a major disease that seriously threatens human health. The latest epidemiological survey results show that the prevalence of CKD in my country is 10.8% (about 120 million). Focal segmental glomerulomerulosclerosis (FSGS) specifically refers to a common primary glomerular disease, with focal and segmental sclerosis as the main pathological features, and the main clinical manifestation is proteinuria , its incidence rate is increasing year by year, and it is very easy to progress to end-stage renal disease (end-stage renal disease, ESRD). Therefore, it is urgent to find a safe and effective method to delay the progress of FSGS. [0003] At present,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/37A61K36/07A61P13/12A61P3/06A61P9/00
CPCA61K36/07A61K36/37A61K2236/331A61P3/06A61P9/00A61P13/12A61K2300/00
Inventor 万凤杨汝春唐玥雯李有贵
Owner HANGHZOU HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com